Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and toxicity for the combination of
Temozolomide and Azacitidine in the treatment of Advanced Soft Tissue Sarcoma or Malignant
Mesothelioma. This is a single-center, open-label, single-arm Phase I dose-escalation trial.
Patients will be evaluated with complete history and physical as well as laboratory studies
(complete blood count, metabolic panel, liver function tests), biopsy, and imaging of all
sites of measurable disease. This study will be conducted over the course of 3 years.